In a phase II study of combined adriamycin, L-PAM, and methotrexate with citrovorum factor rescue, 14 of 15 patients with primary advanced or recurrent ovarian malignant tumors obtained an objective remission. In remission, all patients improved their quality of life. So far the median duration of remission is 5+ months for the complete responders and 7 months for the partial responders. Myelosuppression of varying severity occurred in 93 % of the courses. The regimen proved highly effective, although toxic in some advanced patients.
Get full access to this article
View all access options for this article.
References
1.
BarlowJ. J., PiverM.S., ChuangJ. T., CortesE. P., OhnumaT., HollandJ. F.: Adriamycin and bleomycin, alone and in combination, in gynecologic cancers. Cancer, 32: 735–743, 1973.
2.
BarlowJ. J., PiverM. S.: Methotrexate (NSC-740) with citrovorum factor rescue (NSC-3590), alone and in combination with cyclophosphamide (NSC-26271), in ovarian cancer. Cancer Treat. Rep., 60: 527–553, 1976.
3.
CorbettT. H., GriswoldD. P., MayoJ. G., LasterW. R., SchabelF. M.Jr.: Cyclophosphamide-adriamycin combination chemotherapy of transplantable murine tumors. Cancer Res., 35: 1568–1573, 1975.
4.
De PaloG. M., De LenaM., Di ReF., LucianiL., ValagussaP., BonadonnaG.: Melphalan versus adriamycin in advanced ovarian carcinoma. pp. 188–191. Diagnosis and treatment of ovarian neoplastic alterations. Proc. American Europ. Conference on the Ovary. Montreux, Dec. 9–13, 1974. Excerpta Medica, Amsterdam, 1974.
5.
De VitaV. T.Jr., WassermanT. H., YoungR. C., CarterS. K.: Perspectives on research in gynecologic oncology. Cancer, 28: 509–525, 1976.
6.
FreiE.III, JaffeN., TattersallM. H. N., PitmanS., ParkerL.: New approaches to cancer chemotherapy with methotrexate. New Engl. J. Med., 17: 846–851, 1975.
7.
GoldieJ. H., PriceL. A., HarropK. R.: Methotrexate toxicity: Correlation with duration of administration, plasma levels, dose and excretion pattern. Eur. J. Cancer, 8: 409–414, 1972.
8.
HillB. T., PriceL. A., GoldieJ. H.: The value of adriamycin in overcoming resistance to methotrexate in tissue culture. Eur. J. Cancer, 12: 541–549, 1976.
9.
MattssonW., GynningI., TropéC., ÅstedtB.: Chemotherapy of metastatic carcinoma of the breast. Acta Radiol. Scand., 16: 97–109, 1977.
ParkerL. M., LokichJ. J., GriffithsC. T.: Adriamycin-cyclophosphamide therapy in ovarian cancer. Proc. Am. Ass. Cancer Res. Am. Soc. Clin. Oncol., 16: 263, 1975.
12.
SmithJ. P., RutledgeF.: Chemotherapy in the treatment of cancer of the ovary. Am. J. Obstet. Gynec., 107: 691–703, 1970.
TobiasJ. S., GriffithsT. C.: Management of ovarian carcinoma. New Engl. J. Med., 294: 877–882, 1976.
15.
TropeC., KullanderS., MattssonW., ÅstedtB.: Development of resistance in human ovarian tumours measured by H3-thymidin incorporation into DNA. (To be published 1977).
16.
WassermanT. H., ComisR. L., GoldsmithM., HandelsmanH., PentaJ. S., SlavikM., SoperW. T., CarterS. K.: Tabular analyses of the clinical chemotherapy of solid tumours. Cancer Chemother. Rep., Part. 3. Vol.6: 399–419, 1975.
